Trial reportCancer science2021
Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
Trial report in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Does particle radiation have superior radiobiological advantages for prostate cancer cells? A systematic review of in vitro studies.European journal of medical research · 2022Pooled it
- Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.Cancer science · 2021Trial
- Feasibility of upright carbon ion radiotherapy for prostate cancer: Dosimetric comparison between supine and upright postures.Medical physics · 2026Article
- Survey data analysis of treatment planning methods in particle therapy facilities.Japanese journal of radiology · 2026Article
- Evaluation of Magnetic Resonance Imaging-Derived Synthetic Computed Tomography in Prostate Cancer Carbon Ion Radiotherapy: Impact of Fixation Shell.International journal of particle therapy · 2026Article
- Revisiting fractionation in prostate carbon ion therapy: first comparative analysis of biologically effective dose using mMKM with diverse parameters.Radiation oncology (London, England) · 2026Article
- Survey and profile data on particle therapy technology in Japan.Japanese journal of radiology · 2025Article
- Rectal Gas-Induced Dose Changes in Carbon Ion Radiation Therapy for Prostate Cancer: An In Silico Study.International journal of particle therapy · 2025Article
- Accuracy Evaluation of Dose Warping Using Deformable Image Registration in Carbon Ion Therapy.International journal of particle therapy · 2025Article
- Optimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients.Physics and imaging in radiation oncology · 2025Article
- The first Korean carbon-ion radiation therapy facility: current status of the Heavy-ion Therapy Center at the Yonsei Cancer Center.Radiation oncology journal · 2024Article
- Carbon ion radiation therapy in prostate cancer: The importance of dosage.World journal of radiology · 2024Article
- Correlation between dose-volume parameters and rectal bleeding after 12 fractions of carbon ion radiotherapy for prostate cancer.World journal of radiology · 2024Article
- Inter-fractional error and intra-fractional motion of prostate and dosimetry comparisons of patient position registrations with versus without fiducial markers during treatment with carbon-ion radiotherapy.Radiological physics and technology · 2024Article
- Article
- Carbon ion irradiation exerts antitumor activity by inducing cGAS-STING activation and immune response in prostate cancer-bearing mice.Cancer medicine · 2024Article
- Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer.Journal of cancer research and clinical oncology · 2023Article
- Optimizing 3DCT image registration for interfractional changes in carbon-ion prostate radiotherapy.Scientific reports · 2023Article
- Seed Density as a New Predictive Index of Seed Migration in Brachytherapy for Prostate Cancer Using Iodine-125 Loose Seed.Current oncology (Toronto, Ont.) · 2023Article
- Analysis of the relationship between LET, γH2AX foci volume and cell killing effect of carbon ions using high-resolution imaging technology.Journal of radiation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no clinical reports of long-term follow-up after carbon-ion radiotherapy (CIRT) using a dose of 51.6 Gy (relative biological effectiveness [RBE]) in 12 fractions for localized prostate cancer, or of a comparison of clinical outcomes between passive and scanning beam irradiation. A total of 256 patients with localized prostate cancer who received CIRT at a dose of 51.6 Gy (RBE) in 12 fractions using two different beam delivery techniques (passive [n = 45] and scanning [n = 211]), and who were followed for more than 1 year, were analyzed. The biochemical relapse-free (bRF) rate was defined by the Phoenix definition, and the actuarial toxicity rates were evaluated using the Kaplan-Meier method. Of the 256 patients, 41 (16.0%), 111 (43.4%), and 104 (40.6%) were classified as low, intermediate, and high risk, respectively, after a median follow-up of 7.0 (range 1.1-10.4) years. Androgen deprivation therapy was performed in 212 patients (82.8%). The 5-year bRF rates of the low-, intermediate-, and high-risk patients were 95.1%, 90.9%, and 91.1%, respectively. The 5-year rates of grade 2 late gastrointestinal and genitourinary toxicities in all patients were 0.4% and 6.3%, respectively. No grade ≥3 toxicities were observed. There were no significant differences in the rates of bRF or grade 2 toxicities in patients who received passive irradiation versus scanning irradiation. Our long-term follow-up results showed that a CIRT regimen of 51.6 Gy (RBE) in 12 fractions for localized prostate cancer yielded a good therapeutic outcome and low toxicity rates irrespective of the beam delivery technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.